Characterizing clinical toxicity in cancer combination therapies
Bioinformatics · 2026
DOI: 10.1093/bioinformatics/btag007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioinformatics, 2026. Verfasst von Alexandra M Wong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Computational Molecular Biology, Brown University, Providence, RI 02912, United States. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Computational Biology, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: David & Lucile Packard Fellowship for Science and Engineering.
Abstract (Originalsprache)
Motivation Predicting synergistic cancer drug combinations through computational methods offers a scalable approach to creating therapies that are more effective and less toxic. However, most algorithms focus solely on synergy without considering toxicity when selecting optimal drug combinations. In the absence of combinatorial toxicity assays, a few models use toxicity penalties to balance high synergy with lower toxicity. Still, these penalties have not been explicitly validated against known drug-drug interactions. Results In this study, we examine whether synergy scores and toxicity metrics correlate with known adverse drug interactions. While some metrics show trends with toxicity levels, our results reveal significant limitations in using them as penalties. These findings highlight the challenges of incorporating toxicity into synergy prediction frameworks and suggest that advancing the field requires more comprehensive combination toxicity data. Availability and implementation The code written for this project is available at https://github.com/amw14/toxicity-cancer-drug-combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Computational Molecular Biology, Brown University, Providence, RI 02912, United States.
- Microsoft Research, Cambridge, MA 02142, United States.
ORCID-Profile: Alexandra M Wong, Cecile P G Meier-Scherling, Lorin Crawford
Förderung
- David & Lucile Packard Fellowship for Science and Engineering
Zitieren
APA
Wong, A. M., Meier-Scherling, C. P. G., & Crawford, L. (2026). Characterizing clinical toxicity in cancer combination therapies. Bioinformatics. https://doi.org/10.1093/bioinformatics/btag007
Vancouver
Wong AM, Meier-Scherling CPG, Crawford L. Characterizing clinical toxicity in cancer combination therapies. Bioinformatics. 2026. doi:10.1093/bioinformatics/btag007
BibTeX
@article{Wong2026,
author = {Wong, Alexandra M and Meier-Scherling, Cecile P G and Crawford, Lorin},
title = {Characterizing clinical toxicity in cancer combination therapies},
journal = {Bioinformatics},
year = {2026},
doi = {10.1093/bioinformatics/btag007}
}
EUVIMED